ESMO ASIA 2022: Ethnic diversity and disparities in access to genetic testing impact prostate cancer development and treatment
More than 1.4 million men were diagnosed with prostate cancer in 2020 globally(1), but the…
Browsing: ESMO
ESMO 2022: Highlights on sacituzumab govitecan in HR+/HER2- metastatic breast cancer: TROPiCS-02
ESMO 2022: Highlights on abemaciclib + NSAI in HR+/HER2- advanced breast cancer: The MONARCH 3 Trial
ESMO 2022: Highlights on neo-adjadjuvant vs adjuvant pembrolizumab in resected stage III-IV melanoma: SWOG S1801
ESMO 2022: Highlights on TILs versus ipilimumab in patients with advanced melanoma: The phase 3 study
ESMO 2022: Highlights on ADT duration with post-operative radiotherapy in prostate cancer: RADICALS-HD
ESMO 2022: Highlights on neoadjuvant ICI in locally advanced dMMR colon cancer: The NICHE-2 study
ESMO 2022: Neoadjvuant versus adjuvant pembrolizumab for resected stage III-IV melanoma
“It’s not just what you give, it’s when you give it! SWOG S1801 demonstrates that…
ESMO 2022: Strong potential for neoadjuvant nivolumab plus ipilimumab to become standard of care for locally advanced MMR-deficient colon cancer
“In the NICHE-2 study, two cycles of neoadjuvant nivolumab plus low-dose ipilimumab led to unprecedented…
Pembrolizumab with CRT vs placebo plus CRT for locally advanced HNSCC
Study lead Jean-Pascal Machiels, Cliniques Universitaires Saint-Luc (UCLouvain) and Institut de Recherche Clinique et Expérimentale (Pole…